The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer
Open accessAbstract
Contagious cancers that pass between individuals as an infectious cell line are highly unusual pathogens. Devil facial tumor disease (DFTD) is one such contagious cancer that emerged 16 y ago and is driving the Tasmanian devil to extinction. As both a pathogen and an allograft, DFTD cells should be rejected by the host–immune response, yet DFTD causes 100% mortality among infected devils with no apparent rejection of tumor cells. Why DFTD cells are not rejected has been a question of considerable confusion. Here, we show that DFTD cells do not express cell surface MHC molecules in vitro or in vivo, due to down-regulation of genes essential to the antigen-processing pathway, such as β 2-microglobulin and transporters associated with antigen processing. Loss of gene expression is not due to structural mutations, but to regulatory changes including epigenetic deacetylation of histones. Consequently, MHC class I molecules can be restored to the surface of DFTD cells in vitro by using recombinant devil IFN-γ, which is associated with up-regulation of the MHC class II transactivator, a key transcription factor with deacetylase activity. Further, expression of MHC class I molecules by DFTD cells can occur in vivo during lymphocyte infiltration. These results explain why T cells do not target DFTD cells. We propose that MHC-positive or epigenetically modified DFTD cells may provide a vaccine to DFTD. In addition, we suggest that down-regulation of MHC molecules using regulatory mechanisms allows evolvability of transmissible cancers and could affect the evolutionary trajectory of DFTD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687 · cited 1×
“For instance, down-regulation of class I molecules should make DFTD cells good targets for NK cells (31).”
BackgroundA BIOLOGICAL ROLE FOR THE MAJOR HISTOCOMPATIBILITY ANTIGENS
Doherty, P. C., & Zinkernagel, R. M. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92610-0 · Cited by 492 · cited 1×
“Recognition of allograft cells and malignant cells by the adaptive immune system depends on the interaction of host T cells with highly polymorphic MHC class I and class II molecules (8).”
BackgroundInduction of MHC Class I Expression by the MHC Class II Transactivator CIITA
Martin, B. K., Chin, K.-C., Olsen, J. C., Skinner, C. A., Dey, A., Ozato, K., & Ting, J. P.-Y. (1997) · Immunity · doi:10.1016/s1074-7613(00)80347-7 · Cited by 208
Cited by
Present yourself! by MHC class I and MHC class II molecules
Rock, K. L., Reits, E., & Neefjes, J. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.08.010 · Cited by 814
“This is illustrated by the fact that MHC-deficient oral cancers are currently being transferred between Tasmanian Devils through bites and decimating the population of these animals in the wild [18,19].”
BackgroundBurr, M. L., Sparbier, C. E., Chan, K. L., Chan, Y.-C., Kersbergen, A., Lam, E. Y. N., Azidis-Yates, E., Vassiliadis, D., Bell, C. C., Gilan, O., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.008 · Cited by 649
Self-citationThe urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585
Cancer Epigenetics, Tumor Immunity, and Immunotherapy
Cao, J., & Yan, Q. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.003 · Cited by 346
Conservation of biodiversity in the genomics era
Supple, M. A., & Shapiro, B. (2018) · Genome Biology · doi:10.1186/s13059-018-1520-3 · Cited by 334
Metadata
- Authors
- Siddle, H. V., Kreiss, A., Tovar, C., Yuen, C. K., Cheng, Y., Belov, K., Swift, K., Pearse, A.-M., Hamede, R., Jones, M. E., Skjødt, K., Woods, G. M., & Kaufman, J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2013-03-11
- Volume
- 110
- Issue
- 13
- Pages
- 5103-5108
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1993452367
- Cited by
- 245
- References
- 3
- FWCI
- 14.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.